Axonics announced that the Axonics R20 rechargeable sacral neuromodulation system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20 also provides physicians and their patients with enhanced programming capabilities and expanded MRI labeling.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXNX:
- Axonics responds to ITC action by Medtronic
- Medtronic files ITC action against Axonics
- Axonics reports Q4 EPS 13c, consensus 6c
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Boston Scientific price target raised to $70 from $62 at Wells Fargo
Questions or Comments about the article? Write to editor@tipranks.com